Home › Non-Small Cell Lung Cancer › Pennsylvania › Reading

Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa Reading, PA

9 pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Reading (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Nagre-recruitPhase 3

Reading Hospital, West Reading · 1 mi ang layo
Ephrata Cancer Center, Ephrata · 17 mi ang layo
Sechler Family Cancer Center, Lebanon · 26 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT04267848

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Nagre-recruitPhase 3

Reading Hospital, West Reading · 1 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06498635

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Nagre-recruitPhase 2

McGlinn Cancer Institute Reading Hospital, West Reading · 1 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06667076

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Nagre-recruitPhase 3

Reading Hospital - McGlinn Cancer Institute, West Reading · 1 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06793215

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Nagre-recruitPhase 2

Ephrata Cancer Center, Ephrata · 17 mi ang layo
Sechler Family Cancer Center, Lebanon · 26 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 3, 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Nagre-recruitPhase 2

Ephrata Cancer Center, Ephrata · 17 mi ang layo
Sechler Family Cancer Center, Lebanon · 26 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Nagre-recruitPhase 2/3

Ephrata Cancer Center, Ephrata · 17 mi ang layo
Sechler Family Cancer Center, Lebanon · 26 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Nagre-recruitPhase 2

Ephrata Cancer Center, Ephrata · 17 mi ang layo
Sechler Family Cancer Center, Lebanon · 26 mi ang layo

18 Minutes · Lahat ng kasarian · Na-update May 5, 2026 · NCT06031688

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Nagre-recruitObservasyonal na pag-aaral

Ephrata Cancer Center, Ephrata · 17 mi ang layo
Sechler Family Cancer Center, Lebanon · 26 mi ang layo

Edad 18 pataas · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06418204

Pag-aaral para sa Non-Small Cell Lung Cancer sa ibang lungsod

Iba pang pag-aaral sa Reading

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.